CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial) |
|
|
| Completed | 2 | 43 | Europe | Atezolizumab | Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA | Non-Small Cell Lung Cancer | 02/24 | 02/24 | | |
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). |
|
|
| Not yet recruiting | 2 | 142 | Europe | Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide | Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 08/28 | 06/29 | | |
